CN112151172A - 基于来自医疗机构中多种来源的数据的患者风险评估 - Google Patents
基于来自医疗机构中多种来源的数据的患者风险评估 Download PDFInfo
- Publication number
- CN112151172A CN112151172A CN202010593276.0A CN202010593276A CN112151172A CN 112151172 A CN112151172 A CN 112151172A CN 202010593276 A CN202010593276 A CN 202010593276A CN 112151172 A CN112151172 A CN 112151172A
- Authority
- CN
- China
- Prior art keywords
- patient
- score
- risk
- data
- analysis engine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012502 risk assessment Methods 0.000 title description 36
- 238000004458 analytical method Methods 0.000 claims abstract description 205
- 206010040047 Sepsis Diseases 0.000 claims abstract description 130
- 238000001514 detection method Methods 0.000 claims description 54
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 53
- 206010021639 Incontinence Diseases 0.000 claims description 49
- 230000009471 action Effects 0.000 claims description 36
- 230000004044 response Effects 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 238000009528 vital sign measurement Methods 0.000 claims description 15
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 14
- 238000011156 evaluation Methods 0.000 claims description 14
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 206010053159 Organ failure Diseases 0.000 claims description 6
- 238000004364 calculation method Methods 0.000 claims description 6
- 238000002483 medication Methods 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 89
- 208000014674 injury Diseases 0.000 abstract description 74
- 230000006378 damage Effects 0.000 abstract description 73
- 238000000034 method Methods 0.000 description 77
- 210000002216 heart Anatomy 0.000 description 32
- 230000033001 locomotion Effects 0.000 description 24
- 230000035882 stress Effects 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 19
- 238000004891 communication Methods 0.000 description 19
- 230000006854 communication Effects 0.000 description 19
- 230000005713 exacerbation Effects 0.000 description 19
- 238000012544 monitoring process Methods 0.000 description 18
- 230000036387 respiratory rate Effects 0.000 description 18
- 230000029058 respiratory gaseous exchange Effects 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 206010013975 Dyspnoeas Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 208000000059 Dyspnea Diseases 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000036760 body temperature Effects 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 206010038687 Respiratory distress Diseases 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 206010011703 Cyanosis Diseases 0.000 description 6
- 206010012218 Delirium Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 206010069351 acute lung injury Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- -1 hematocrit Chemical compound 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000001953 Hypotension Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229940005483 opioid analgesics Drugs 0.000 description 5
- 238000013186 photoplethysmography Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002106 pulse oximetry Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 4
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 4
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000032274 Encephalopathy Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000000616 Hemoptysis Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000003339 best practice Methods 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 206010016803 Fluid overload Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 229910003798 SPO2 Inorganic materials 0.000 description 3
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 238000013473 artificial intelligence Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 208000018578 heart valve disease Diseases 0.000 description 3
- 238000011540 hip replacement Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000012806 monitoring device Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000097 Abdominal tenderness Diseases 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010003504 Aspiration Diseases 0.000 description 2
- 206010003598 Atelectasis Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 239000003154 D dimer Substances 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229940097420 Diuretic Drugs 0.000 description 2
- 208000012258 Diverticular disease Diseases 0.000 description 2
- 206010013554 Diverticulum Diseases 0.000 description 2
- 208000003870 Drug Overdose Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 108091005515 EGF module-containing mucin-like hormone receptors Proteins 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037194 Fever of Unknown Origin Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010067660 Heart valve incompetence Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 101710196709 Inosamine-phosphate amidinotransferase 1 Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 206010031123 Orthopnoea Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 206010033296 Overdoses Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 206010068513 Pulmonary renal syndrome Diseases 0.000 description 2
- 101710141119 Putative inosamine-phosphate amidinotransferase 2 Proteins 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 208000008475 Smoke Inhalation Injury Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 238000009167 androgen deprivation therapy Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000012696 congenital leptin deficiency Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 231100000725 drug overdose Toxicity 0.000 description 2
- 238000002079 electron magnetic resonance spectroscopy Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002297 emergency surgery Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 229960000610 enoxaparin Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000010295 mobile communication Methods 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000012144 orthopnea Diseases 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 201000003144 pneumothorax Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000002644 respiratory therapy Methods 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000015121 Cardiac valve disease Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 208000005018 Hyperlactatemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000007175 bidirectional communication Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 238000001441 oximetry spectrum Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000012327 purpuric rash Diseases 0.000 description 1
- 230000003016 quadriplegic effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000024470 urgency of urination Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000006498 vasomotor response Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/02028—Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
- A61B5/02055—Simultaneously evaluating both cardiovascular condition and temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1113—Local tracking of patients, e.g. in a hospital or private home
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1113—Local tracking of patients, e.g. in a hospital or private home
- A61B5/1115—Monitoring leaving of a patient support, e.g. a bed or a wheelchair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G7/00—Beds specially adapted for nursing; Devices for lifting patients or disabled persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G7/00—Beds specially adapted for nursing; Devices for lifting patients or disabled persons
- A61G7/05—Parts, details or accessories of beds
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Abstract
Description
评估 | qSOFA分数 |
低血压(SBP≤100mmHg) | 1 |
高呼吸频率(≥22breaths/min) | 1 |
改变心理状态(GCS≤14) | 1 |
PaO<sub>2</sub>/FiO<sub>2</sub>(mmHg) | SOFA分数 |
≥400 | 0 |
<400 | +1 |
<300 | +2 |
<200且机械通风 | +3 |
<100且机械通风 | +4 |
格拉斯哥昏迷量表 | SOFA分数 |
15 | 0 |
13-14 | +1 |
10-12 | +2 |
6-9 | +3 |
<6 | +4 |
血小板<sup>x</sup>10<sup>3</sup>/μl | SOFA分数 |
≥150 | 0 |
<150 | +1 |
<100 | +2 |
<50 | +3 |
<20 | +4 |
肌酸酐(mg/dl)[μmol/L](或尿量) | SOFA分数 |
<1.2[<110] | 0 |
1.2–1.9[110-170] | +1 |
2.0–3.4[171-299] | +2 |
3.5–4.9[300-440](or<500ml/d) | +3 |
>5.0[>440](or<200ml/d) | +4 |
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/456,712 | 2019-06-28 | ||
US16/456,712 US11908581B2 (en) | 2018-04-10 | 2019-06-28 | Patient risk assessment based on data from multiple sources in a healthcare facility |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112151172A true CN112151172A (zh) | 2020-12-29 |
Family
ID=71266397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010593276.0A Pending CN112151172A (zh) | 2019-06-28 | 2020-06-26 | 基于来自医疗机构中多种来源的数据的患者风险评估 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3758026A1 (zh) |
CN (1) | CN112151172A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114708972A (zh) * | 2022-06-06 | 2022-07-05 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | 一种vte风险预警系统 |
US20230137904A1 (en) * | 2021-10-28 | 2023-05-04 | Xsensor Technology Corporation | System and method for generating and visualizing virtual figures from pressure data captured using weight support devices for visualization of user movement |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112750513B (zh) * | 2020-12-31 | 2024-04-05 | 复旦大学附属华山医院 | 甲状旁腺切除术患者管理系统及方法 |
CN112885484A (zh) * | 2021-01-22 | 2021-06-01 | 中科朗劢技术有限公司 | 一种用于感染管理的可视化监测预警方法 |
CN113270196B (zh) * | 2021-05-25 | 2023-07-14 | 郑州大学 | 一种脑卒中复发风险感知与行为决策模型构建系统及方法 |
CN113555128A (zh) * | 2021-06-25 | 2021-10-26 | 南通大学附属医院 | 慢性疼痛互联网+管理平台及其构建方法 |
CN113764103A (zh) * | 2021-08-19 | 2021-12-07 | 海兹凯尔医疗科技(上海)有限公司 | 一种基于互联网的女性生殖健康管理系统和方法 |
CN113658702B (zh) * | 2021-08-26 | 2023-09-15 | 山西慧虎健康科技有限公司 | 基于中医望诊的脑卒中特征提取与智能风险预测方法及系统 |
CN113555123A (zh) * | 2021-08-27 | 2021-10-26 | 复旦大学附属中山医院 | 胆囊癌患者放化疗后生存获益的预测模型建立方法 |
CN113599120A (zh) * | 2021-09-06 | 2021-11-05 | 温州隐枫医疗器械有限公司 | 一种儿科用新生儿清洁辅助调节系统 |
CN114767445B (zh) * | 2022-04-15 | 2023-05-23 | 永康市第一人民医院 | 一种孕妇分娩用辅助装置 |
CN114698583B (zh) * | 2022-05-17 | 2023-04-28 | 青岛国信蓝色硅谷发展有限责任公司 | 工厂化鱼类养殖智能溶解氧自调控方法及其系统 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267791A1 (en) * | 2008-05-12 | 2013-10-10 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
US20150120324A1 (en) * | 2013-10-25 | 2015-04-30 | Cerner Innovation, Inc. | Integrating pre-hospital encounters into an electronic medical record |
CN106570309A (zh) * | 2016-10-02 | 2017-04-19 | 张家港市锦丰镇人民医院 | 一种护理风险综合评估方法 |
US20190115093A1 (en) * | 2016-04-15 | 2019-04-18 | Koninklijke Philips N.V. | Annotating data points associated with clinical decision support application |
US20190180875A1 (en) * | 2017-12-12 | 2019-06-13 | Medical Informatics Corporation | Risk monitoring scores |
US20190307405A1 (en) * | 2018-04-10 | 2019-10-10 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897780B2 (en) | 1993-07-12 | 2005-05-24 | Hill-Rom Services, Inc. | Bed status information system for hospital beds |
US5561412A (en) | 1993-07-12 | 1996-10-01 | Hill-Rom, Inc. | Patient/nurse call system |
US5838223A (en) | 1993-07-12 | 1998-11-17 | Hill-Rom, Inc. | Patient/nurse call system |
US5699038A (en) | 1993-07-12 | 1997-12-16 | Hill-Rom, Inc. | Bed status information system for hospital beds |
US7319386B2 (en) | 2004-08-02 | 2008-01-15 | Hill-Rom Services, Inc. | Configurable system for alerting caregivers |
US7253366B2 (en) | 2004-08-09 | 2007-08-07 | Hill-Rom Services, Inc. | Exit alarm for a hospital bed triggered by individual load cell weight readings exceeding a predetermined threshold |
WO2009036150A2 (en) * | 2007-09-11 | 2009-03-19 | Aid Networks, Llc | Wearable wireless electronic patient data communications and physiological monitoring device |
US8384526B2 (en) | 2008-02-22 | 2013-02-26 | Hill-Rom Services, Inc. | Indicator apparatus for healthcare communication system |
JP2012502671A (ja) * | 2008-05-12 | 2012-02-02 | アーリーセンス エルティディ | 臨床症状のモニタリング、予測及び治療 |
US8779924B2 (en) | 2010-02-19 | 2014-07-15 | Hill-Rom Services, Inc. | Nurse call system with additional status board |
US20120316892A1 (en) | 2011-06-08 | 2012-12-13 | Huster Keith A | System and method of bed data aggregation, normalization and communication to third parties |
US20140276504A1 (en) | 2013-03-13 | 2014-09-18 | Hill-Rom Services, Inc. | Methods and apparatuses for the detection of incontinence or other moisture, methods of fluid analysis, and multifunctional sensor systems |
US10528701B2 (en) * | 2015-02-17 | 2020-01-07 | Massachusetts Institute Of Technology | System and method for sepsis care task management |
WO2017004240A1 (en) * | 2015-06-30 | 2017-01-05 | Ishoe, Inc | Identifying fall risk using machine learning algorithms |
US10206630B2 (en) * | 2015-08-28 | 2019-02-19 | Foresite Healthcare, Llc | Systems for automatic assessment of fall risk |
CA3001490C (en) | 2015-11-09 | 2024-03-19 | Wiser Systems, Inc. | Methods for synchronizing multiple devices and determining location based on the synchronized devices |
WO2017087452A1 (en) | 2015-11-16 | 2017-05-26 | Hill-Rom Services, Inc. | Incontinence detection systems for hospital beds |
US10653567B2 (en) | 2015-11-16 | 2020-05-19 | Hill-Rom Services, Inc. | Incontinence detection pad validation apparatus and method |
US11179095B2 (en) * | 2016-04-29 | 2021-11-23 | University Of Virginia Patent Foundation | Method, system, and apparatus for remote patient monitoring or tracking of sepsis-related indicators |
US11172892B2 (en) | 2017-01-04 | 2021-11-16 | Hill-Rom Services, Inc. | Patient support apparatus having vital signs monitoring and alerting |
EP3879459A1 (en) | 2017-08-29 | 2021-09-15 | Hill-Rom Services, Inc. | Rfid tag inlay for incontinence detection pad |
US10957445B2 (en) | 2017-10-05 | 2021-03-23 | Hill-Rom Services, Inc. | Caregiver and staff information system |
-
2020
- 2020-06-26 CN CN202010593276.0A patent/CN112151172A/zh active Pending
- 2020-06-26 EP EP20182715.1A patent/EP3758026A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267791A1 (en) * | 2008-05-12 | 2013-10-10 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
US20150120324A1 (en) * | 2013-10-25 | 2015-04-30 | Cerner Innovation, Inc. | Integrating pre-hospital encounters into an electronic medical record |
US20190115093A1 (en) * | 2016-04-15 | 2019-04-18 | Koninklijke Philips N.V. | Annotating data points associated with clinical decision support application |
CN106570309A (zh) * | 2016-10-02 | 2017-04-19 | 张家港市锦丰镇人民医院 | 一种护理风险综合评估方法 |
US20190180875A1 (en) * | 2017-12-12 | 2019-06-13 | Medical Informatics Corporation | Risk monitoring scores |
US20190307405A1 (en) * | 2018-04-10 | 2019-10-10 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230137904A1 (en) * | 2021-10-28 | 2023-05-04 | Xsensor Technology Corporation | System and method for generating and visualizing virtual figures from pressure data captured using weight support devices for visualization of user movement |
CN114708972A (zh) * | 2022-06-06 | 2022-07-05 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | 一种vte风险预警系统 |
CN114708972B (zh) * | 2022-06-06 | 2022-09-02 | 安徽省第二人民医院(安徽医学高等专科学校附属医院、安徽省职业病防治院) | 一种vte风险预警系统 |
Also Published As
Publication number | Publication date |
---|---|
EP3758026A1 (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6896915B2 (ja) | 医療施設の複数のソースからのデータに基づく患者リスク評価 | |
US11908581B2 (en) | Patient risk assessment based on data from multiple sources in a healthcare facility | |
CN112151172A (zh) | 基于来自医疗机构中多种来源的数据的患者风险评估 | |
US20200066415A1 (en) | Interfaces displaying patient data | |
Gokalp et al. | Integrated telehealth and telecare for monitoring frail elderly with chronic disease | |
US9549705B2 (en) | Apparatuses for supporting and monitoring a condition of a person | |
US8844073B2 (en) | Apparatus for supporting and monitoring a person | |
CN108348163A (zh) | 设计用于数字健康管理和远程患者监测支持的移动平台的系统和方法 | |
Sahu et al. | Vital sign monitoring system for healthcare through IoT based personal service application | |
US20210065856A1 (en) | Patient management based on sensed inputs | |
EP3767637A1 (en) | Personalized baselines, visualizations, and handoffs | |
CN112786199A (zh) | 显示患者数据的界面 | |
WO2022044172A1 (ja) | ソフトウェア、健康状態判定装置及び健康状態判定方法 | |
KR20040034164A (ko) | 간병용로봇장치 및 간병로봇 모니터링시스템 | |
US20230190209A1 (en) | Personalized alarm settings | |
Chirchi et al. | Context Monitoring of Patients using Wireless Network | |
US20230301602A1 (en) | Information processing device, information processing method, and storage medium | |
EP4024409A1 (en) | Monitoring system for pressure injury | |
Clarke | Integrated Telehealth and Telecare for Monitoring Frail elderly with Chronic Disease | |
TWM599463U (zh) | 心肺功能病患之居家照護系統 | |
JP2019213888A (ja) | 見守りシステム | |
KR20130135654A (ko) | U 헬스 건강관리 모니터링 시스템 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: S Cather Inventor after: S. Fox Inventor after: S. A. Fitzgibbons Inventor after: J. Derby Inventor after: 50. A. zapfei Inventor after: J. Cha har Inventor after: E. Urutia Inventor after: Keegan Christopher Inventor after: K. Brown Inventor after: E. Montabi Inventor before: S Cather Inventor before: S. Fox Inventor before: S. A. Fitzgibbons Inventor before: J. Derby Inventor before: 50. A. zapfei Inventor before: J. Cha har Inventor before: E. Urutia Inventor before: Keegan Christopher Inventor before: K. Schwenser Inventor before: E. Montabi |
|
CB03 | Change of inventor or designer information |